Australia's universal healthcare system was built on the promise that medical fate would not follow financial fortune — yet a study of more than 4,400 myeloma patients reveals that postcode still shapes prognosis. Across 44 sites and over a decade of diagnoses, patients from lower-income neighbourhoods were less likely to receive life-extending stem cell transplants and survived, on average, fourteen months less than their wealthier counterparts. The findings do not indict the principle of universal care so much as they illuminate how structural and social forces persist beneath the surface of
Wealth Gap Widens Myeloma Survival Odds Even in Universal Healthcare
Lower-SES myeloma patients experience significantly reduced survival outcomes, with approximately 14 months shorter median lifespan compared to higher-SES counterparts.
Your postcode remains part of your prognosis
Mark
If Australia has universal healthcare, why would neighbourhood wealth matter at all?
Mimi
Because universal healthcare removes the financial barrier at the clinic door, but it doesn't remove everything else—transportation, time off work, knowing which questions to ask, whether a doctor thinks you're a good candidate for an aggressive treatment.
Mark
So these patients were being denied the transplant outright?
Mimi
Not always denied. More often delayed, or never referred in the first place. The data shows they were less likely to receive it, and when they did, they waited longer. That delay itself can be fatal in cancer.
Mark
Could it just be that sicker patients live in poorer neighbourhoods, and sicker patients don't survive transplant?
Mimi
The researchers controlled for that. They looked at baseline health—weight, function, existing diseases—and the gap remained. It's not that these patients were too sick. It's that they weren't getting the treatment.
Mark
Fourteen months is a lot of life.
Mimi
It is. That's the median difference between low and high income areas. Some people live longer, some shorter, but on average, your neighbourhood predicts whether you see your child graduate.
Mark
What would actually fix this?
Mimi
That's what they're asking. You have to find the barriers first—is it access to the clinic? Information? Clinician assumptions? Once you know, you can remove them.
Il Polso
- A fourteen-month survival gap between the poorest and wealthiest myeloma patients has emerged from within a healthcare system explicitly designed to prevent such inequity.
- Lower-SES patients arrived at diagnosis already carrying heavier burdens — greater comorbidities, weaker physical function — yet the treatment disparity persisted even after accounting for these differences.
- High-income patients were one and a half times more likely to receive an autologous stem cell transplant, the standard intervention with proven survival benefit, and when lower-SES patients did receive it, they waited significantly longer.
- The persistence of disparity independent of biological factors points to structural barriers — transport, workplace inflexibility, system navigation, referral patterns — that universal insurance alone cannot dissolve.
- Researchers are calling for targeted investigation into these non-biological barriers, framing equitable access not as an aspiration already achieved but as unfinished policy work with measurable human cost.
Australia's universal healthcare system was built on the promise that medical fate would not follow financial fortune — yet a study of more than 4,400 myeloma patients reveals that postcode still shapes prognosis. Across 44 sites and over a decade of diagnoses, patients from lower-income neighbourhoods were less likely to receive life-extending stem cell transplants and survived, on average, fourteen months less than their wealthier counterparts. The findings do not indict the principle of universal care so much as they illuminate how structural and social forces persist beneath the surface of formal equality, quietly sorting people into different futures.
Australia's universal healthcare system removes the financial barrier at the point of care — no one is turned away for inability to pay. Yet a decade-long study of more than 4,400 myeloma patients across 44 sites has found that neighbourhood wealth still quietly determines who receives the most effective treatment, and who survives longest.
Researchers sorted patients diagnosed between mid-2012 and late 2025 into low, medium, and high socioeconomic brackets using postcode data. Patients from poorer neighbourhoods arrived sicker — higher rates of diabetes, heart disease, and reduced physical function — but the disparities in care went beyond what those baseline differences could explain. The critical intervention in myeloma, an autologous stem cell transplant, was significantly less likely to be offered to lower-SES patients. High-income patients were one and a half times more likely to receive it, and when lower-income patients did, they waited longer to get there.
The survival figures are unambiguous. Low-SES patients had a median overall survival of 78.5 months. Medium-SES patients survived 86.7 months. High-SES patients reached 92.5 months. The fourteen-month gap between the poorest and wealthiest is not a statistical abstraction — in a disease where new therapies add weeks or months at a time, it is the difference between milestones reached and milestones missed.
What makes the findings particularly pointed is that they emerged from inside a system designed to prevent exactly this outcome. Because the disparities held even after controlling for patients' underlying health, the causes appear structural rather than biological: transportation barriers, difficulty taking time off work, less familiarity with navigating specialist referrals, or patterns in clinical decision-making. The researchers stop short of naming a single cause, but their conclusion is clear — in Australia as elsewhere, postcode remains part of prognosis, and identifying the specific barriers that persist beneath universal coverage is now the urgent work.
Australia's universal healthcare system was supposed to level the playing field. Yet a study of more than 4,400 myeloma patients reveals that where you live—and what your neighbourhood's wealth looks like—still determines whether you live longer or die sooner, even when the same treatments are theoretically available to everyone.
Researchers at 44 Australian sites tracked patients diagnosed with multiple myeloma between mid-2012 and late 2025, sorting them by neighbourhood socioeconomic status using postcode data. The groups were roughly equal in size: about 1,460 patients in each of the low, medium, and high socioeconomic brackets. What they found was stark. Patients from poorer neighbourhoods not only started out sicker—they had higher body weight, weaker physical function, and more existing conditions like diabetes and heart disease—but they also received fundamentally different treatment, with measurably worse results.
The critical intervention in myeloma care is an autologous stem cell transplant, a standard procedure that has proven survival benefit. Yet patients from low-income areas were significantly less likely to receive it. When researchers accounted for all the baseline health differences that might explain this gap, the disparity remained. High-income patients were 1.5 times more likely to get the transplant than low-income patients. Even when low-income patients did receive it, they waited longer—the time from initial treatment to transplant was significantly extended, a delay that matters when you're fighting cancer.
The survival numbers tell the story most plainly. Patients from low-income neighbourhoods had a median overall survival of 78.5 months—six and a half years. Those from medium-income areas survived 86.7 months. Those from high-income areas made it to 92.5 months. The gap between the poorest and richest was fourteen months. In a disease where every month counts, where new drugs and interventions can add weeks or months to life, this is not a rounding error. It is the difference between seeing your child graduate or not, between one more Christmas or none.
What makes this finding particularly uncomfortable is that it emerged from within a healthcare system explicitly designed to prevent exactly this outcome. Australia's universal system removes the financial barrier at the point of care. No one is turned away because they cannot pay. Yet the disparities persisted anyway, independent of the health conditions patients brought with them to diagnosis. This suggests the barriers are subtler and more structural: perhaps difficulty getting time off work for appointments, transportation challenges in remote areas, less familiarity with the healthcare system, or clinician bias in who gets referred for transplant.
The researchers were careful not to overstate their findings, but the implication is clear. In a system where treatment access should be equal, socioeconomic status—a non-biological factor entirely—was still driving who got the therapy most likely to extend their life. The study calls for further investigation into what those barriers actually are, so they can be removed. Until then, in Australia as elsewhere, your postcode remains part of your prognosis.
Citazioni salienti
Non-biological factors continue to influence access to standard-of-care therapy and survival, warranting further research to identify and address barriers to equitable care— Study authors
Vuoi la storia completa?
Leggi l'originale su nature.com ↗
Health & Medicine